MSFT   183.34 (-1.09%)
GOOGL   1,417.25 (-1.53%)
AMZN   2,469.01 (-0.38%)
NVDA   350.63 (-0.04%)
T   31.59 (+0.25%)
ACB   14.17 (-0.91%)
BA   183.02 (+5.69%)
MSFT   183.34 (-1.09%)
GOOGL   1,417.25 (-1.53%)
AMZN   2,469.01 (-0.38%)
NVDA   350.63 (-0.04%)
T   31.59 (+0.25%)
ACB   14.17 (-0.91%)
BA   183.02 (+5.69%)
MSFT   183.34 (-1.09%)
GOOGL   1,417.25 (-1.53%)
AMZN   2,469.01 (-0.38%)
NVDA   350.63 (-0.04%)
T   31.59 (+0.25%)
ACB   14.17 (-0.91%)
BA   183.02 (+5.69%)
MSFT   183.34 (-1.09%)
GOOGL   1,417.25 (-1.53%)
AMZN   2,469.01 (-0.38%)
NVDA   350.63 (-0.04%)
T   31.59 (+0.25%)
ACB   14.17 (-0.91%)
BA   183.02 (+5.69%)
Log in

NASDAQ:DMPIDelMar Pharmaceuticals Stock Price, Forecast & News

$0.85
+0.03 (+3.74 %)
(As of 06/4/2020 12:38 PM ET)
Add
Compare
Today's Range
$0.82
Now: $0.85
$0.90
50-Day Range
$0.51
MA: $0.68
$1.03
52-Week Range
$0.38
Now: $0.85
$2.66
Volume3,118 shs
Average Volume704,001 shs
Market Capitalization$9.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.
Read More
DelMar Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMPI
CUSIPN/A
Phone858-350-4364

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.13) per share

Profitability

Net Income$-8,050,000.00

Miscellaneous

Employees4
Market Cap$9.72 million
Next Earnings Date9/8/2020 (Estimated)
OptionableNot Optionable

Receive DMPI News and Ratings via Email

Sign-up to receive the latest news and ratings for DMPI and its competitors with MarketBeat's FREE daily newsletter.

DelMar Pharmaceuticals (NASDAQ:DMPI) Frequently Asked Questions

How has DelMar Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

DelMar Pharmaceuticals' stock was trading at $0.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DMPI stock has increased by 63.6% and is now trading at $0.8507. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DelMar Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DelMar Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DelMar Pharmaceuticals.

When is DelMar Pharmaceuticals' next earnings date?

DelMar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, September 8th 2020. View our earnings forecast for DelMar Pharmaceuticals.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) released its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.06. View DelMar Pharmaceuticals' earnings history.

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

Shares of DelMar Pharmaceuticals reverse split on Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for DMPI?

2 brokerages have issued 1-year target prices for DelMar Pharmaceuticals' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate DelMar Pharmaceuticals' share price to reach $2.00 in the next year. This suggests a possible upside of 135.1% from the stock's current price. View analysts' price targets for DelMar Pharmaceuticals.

Has DelMar Pharmaceuticals been receiving favorable news coverage?

Media stories about DMPI stock have trended somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. DelMar Pharmaceuticals earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutDelMar Pharmaceuticals.

Who are some of DelMar Pharmaceuticals' key competitors?

What other stocks do shareholders of DelMar Pharmaceuticals own?

Who are DelMar Pharmaceuticals' key executives?

DelMar Pharmaceuticals' management team includes the following people:
  • Mr. Saiid Zarrabian B.Sc., MBA, Pres, CEO & Director (Age 66)
  • Mr. Jeffrey A. Bacha, Founder (Age 51)
  • Dr. Dennis M. Brown, Co-Founder & Chief Scientific Officer (Age 69)
  • Mr. Scott Praill CA, CPA, BSc, CFO & Sec. (Age 52)

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

How do I buy shares of DelMar Pharmaceuticals?

Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DelMar Pharmaceuticals' stock price today?

One share of DMPI stock can currently be purchased for approximately $0.85.

How big of a company is DelMar Pharmaceuticals?

DelMar Pharmaceuticals has a market capitalization of $9.72 million. The company earns $-8,050,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. DelMar Pharmaceuticals employs 4 workers across the globe.

What is DelMar Pharmaceuticals' official website?

The official website for DelMar Pharmaceuticals is www.delmarpharma.com.

How can I contact DelMar Pharmaceuticals?

DelMar Pharmaceuticals' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-350-4364 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.